Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of third-generation EGFR-TKI plus metronomic vinorelbine in first-line EGFR-mutant advanced NSCLC
ChiCTR2200058432Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib and vinorelbine in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: progression-free survival, disease control rate and 3 more. Started Apr 2022; status: recruiting.
02
Drugs
osimertinibvinorelbine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200058432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058432.